



[Handwritten signature]
**ATTORNEY DOCKET NO. 14014.0347U3
PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of)
Berzofsky et al.) Art Unit: Unassigned
Application No. 10/770,117) Examiner: Unassigned
Filing Date: February 2, 2004) Confirmation No. Unassigned
For: "MODIFIED HCV PEPTIDE)
VACCINES")

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 36339

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Form PTO-1449 is a listing of documents known to Applicants and/or their attorneys. All of the documents cited were cited by or submitted to the Patent Office in Application No. 09/763,260, filed August 17, 1999, to which the present application claims priority. Pursuant to 37 C.F.R. § 1.98(d), copies of these documents are not enclosed.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(3), in that a first Office Action on the merits of the present patent application has not yet been mailed to Applicants.


Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

**ATTORNEY DOCKET NO. 14014.0347U3
APPLN. NO. 10/770,117**

No fee is believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.





Bruce H. Becker, M.D.
Registration No. 48,884

NEEDLE & ROSENBERG, P.C.
Customer Number 36339
(678) 420-9300
(678) 420-9301 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.


Bruce H. Becker, M.D.


Date



Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF INFORMATION CITED BY APPLICANT (Use as many sheets as necessary)				Complete if Known			
				Application Number		10/770,117	
				Filing Date		February 2, 2004	
				First Named Inventor		Berzofsky	
				Group Art Unit		Unassigned	
				Examiner Name		Unassigned	
U.S. PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
		5,709,995	1/1998	Chisari et al.			
FOREIGN PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name		Translation Yes/No	
		WO 97/41440	11/06/97	Van der burg et al.			
		WO 95/27733	10/19/95	Berzofsky et al.			
		WO 95/12677	05/11/95	Leroux-Roels et al.			
NON-PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)					
		Ahlers et al. "Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence," <i>Proc. Natl. Acad. Sci. USA</i> , 94:10856-10861 (September 1997)					
		Hudrisier et al., "Relative Implication of Peptide Residues in Binding to Major Histocompatibility Complex Class I H-2Db: Application to the Design of High-Affinity, Allele-Specific Peptides," <i>Molecular Immunology</i> 32:895-907 (1995)					
		Kalams et al., "T Cell Receptor Usage and Fine Specificity of Human Immunodeficiency Virus I-specific Cytotoxic T Lymphocyte Clones," <i>Journal of Experimental Medicine</i> 183:1669-1679 (1996)					
		Parker et al., "Sequence motifs important for peptide binding to the human MHC class I molecule HLA-A2," <i>The Journal of Immunology</i> 149:3580-3587 (1992)					
		Sarobe et al. "Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions," <i>J. Clin. Invest.</i> , 102(6):1239-1248 (September 1998)					
		Shirai et al. "CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1," <i>J. Immunol.</i> , 154(6):2733-2742 (March 1995)					
Examiner Signature:				Date Considered:			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							